We have an updated report [Version - 2024] available. Kindly sign up to get the sample of the report.
all report title image

ANTIPARASITIC DRUGS MARKET ANALYSIS

Antiparasitic Drugs Market, By Product Type (Anthelmintics (Anticestodal Drugs, Antitrematodal Drugs, and Antinematodal Drugs) Antiprotozoal Agents (Antimalarials Agents Antibabesial Agents, Antiamoebic Agents, and Others (Trypanocidal Agents, Antileishmanial Agents, etc.)), Ectoparasiticide (Antiscabietic Agents and Pediculicides)), By Route Of Administration (Oral, Injectable, and Topical), By Application (Human Health, Animal Health, Crop Health) and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) -

  • Published In : Jun 2023
  • Code : CMI3782
  • Pages :212
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Global antiparasitic drugs market is estimated to be valued at US$ 23.40 billion in 2023 and is expected to exhibit a CAGR of 5.6% during the forecast period (2023-2030).

Analysts’ Views on Global Antiparasitic Drugs Market:

The global antiparasitic drugs market has been experiencing steady growth due to several factors. One of the primary drivers is the high prevalence of parasitic infections, such as malaria, helminthiasis, and other neglected tropical diseases, particularly in developing countries. The increasing awareness about these diseases and the need for their effective treatment has led to a growing demand for antiparasitic drugs.

Analysts have observed a trend towards the development of novel antiparasitic drugs and the improvement of existing treatment options. This includes exploration of the new drug targets and the discovery of potential combination therapies to enhance efficacy and reduce the risk of drug resistance.

Figure 1. Global Antiparasitic Drugs Market Share (%), By Product Type, 2023

ANTIPARASITIC DRUGS MARKET

To learn more about this report, Request sample copy

Global Antiparasitic Drugs Market– Drivers

OIE (Office International des Epizooties) guide promotes responsible anthelmintic drug use

Guidance published by Office International des Epizooties in 2022 describes the dangers of resistance to deworming drugs and the ways people responsible for animal care can help preserve drug effectiveness.

For instance, in 2022, The World Organization for Animal Health is provided the document, “Responsible and Prudent Use of Anthelmintic Chemicals to Help Control Anthelmintic Resistance in Grazing Livestock Species” (PDF). The guidance contains messages on how veterinarians, animal owners and caretakers, and governmental authorities can help protect animal health and welfare through careful drug administration.

According to the guidance, the purpose of this document is to encourage responsible utilization of the limited range of anthelmintic chemicals that are still accessible for managing parasites. The focus is specifically on their appropriate application in ruminant animals used in food production, such as sheep, goats, and cattle.

 Figure 2. Global Antiparasitic Drugs Market Value (US$ Billion), By Region, 2023

ANTIPARASITIC DRUGS MARKET

To learn more about this report, Request sample copy

Global Antiparasitic Drugs Market- Regional Analysis

Among region, North America is estimated to hold a dominant position in the global antiparasitic drugs market over the forecast period, as in 2022-2023 every two minutes, a child dies of malaria. And each year, more than 200 Billion new cases of the disease are reported globally. Malaria remains a threat to the U.S. travellers, the military, and to the U.S. citizens living abroad. Prevention messages need to be reinforced, but global efforts to control or eliminate the disease help reduce the risk for everyone. For that Co-implement the event by U.S. President’s Malaria Initiative (PMI), led by The United States Agency for International Development (USAID) is organized.

Global Antiparasitic Drugs Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.

Antiparasitic drugs were initially considered as a potential treatment option for the disease. While numerous papers have examined the effectiveness of different antiparasitic drugs in treating COVID-19 individually, there has been a lack of comprehensive studies encompassing these drugs as a whole. This particular study aims to provide a review of recommended antiparasitic drugs for COVID-19 treatment, discussing their functions, in vitro testing, and clinical results.

The Food and Drug Administration approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, as ivermectin is antiparasitic drug. Ivermectin, an antiparasitic drug, has been suggested as a potential treatment for the current COVID-19 pandemic caused by SARS-CoV-2. This virus is an RNA virus closely related to the severe acute respiratory syndrome coronavirus (SARS-CoV). Previous studies on SARS-CoV have indicated that a protein called IMPα/β1 may play a role in the virus's ability to enter the nucleus of host cells by shutting down the movement of the viral nucleocapsid protein. This process has been linked to the impact on host cell division. Another protein, ORF6, found in SARS-CoV, has been shown to counteract the antiviral activity of a transcription factor called STAT1 by trapping IMPα/β1 on the membrane of the rough endoplasmic reticulum and Golgi apparatus. Based on these findings, it has been suggested that ivermectin's ability to inhibit nuclear transport may be effective against SARS-CoV-2.

Antiparasitic Drugs Market Report Coverage

Report Coverage Details
Base Year: 2022 Market Size in 2023: US$ 23.40 Bn
Historical Data for: 2018 to 2021 Forecast Period: 2023 to 2030
Forecast Period 2023 to 2030 CAGR: 5.6% 2030 Value Projection: US$ 34.34 Bn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Product Type: Anthelmintics (Anticestodal Drugs, Antitrematodal Drugs, Antinematodal Drugs) Antiprotozoal Agents(Antimalarials Agents, Antibabesial Agents, Antiamoebic Agents, Others (Trypanocidal Agents, Antileishmanial Agents, etc.)) Ectoparasiticide (Antiscabietic Agents, Pediculicides)
  • By Route of Administration: Oral, Injectable, Topical
  • By Application: Human Health, Animal Health, Crop Health
Companies covered:

Merck KGaA, GlaxoSmithKline plc, Dr. Reddy’s Laboratories Ltd, Cipla Limited, Cadila Pharmaceuticals, Watson International Limited, Vivaldis, Glenmark Pharmaceuticals Limited, Viatris Inc., Novartis AG, AdvaCare Pharma, Lupin, Sun Pharmaceutical Industries Ltd., and Aurobindo Pharma

Growth Drivers:
  • OIE guide promotes responsible anthelmintic drug use
Restraints & Challenges:
  • Rising resistance to antimalarial drug regimens

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Global Antiparasitic Drugs Market- Segmentation

Global antiparasitic drugs market report is segmented into by product type, by route of administration, by application, and by region.

Based on Product Type, the market is segmented into anthelmintic (Anticestodal Drugs, Antitrematodal Drugs, Antinematodal Drugs), antiprotozoal (Antimalarials Agents Antibabesial Agents, Antiamoebic Agents, Others (Trypanocidal Agents, Antileishmanial Agents, etc.)) agents and ectoparasiticide (Antiscabietic Agents, Pediculicides). Out of which, anthelmintic segment is expected to hold a dominant position in the global antiparasitic drugs market during the forecast period as OIE guide promotes responsible anthelmintic drug use.

Based on Route of Administration, the market is segmented into oral, injectable, and topical. Out of which, injectable segment is expected to dominate the market over the forecast period, as for most parasitic infections, tissue penetration of the antiparasitic drugs is essential for clinical success of the treatment.

Based on Region, global Antiparasitic Drugs market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. Out of which, North America is expected to dominate the market over the forecast period, Co-implement the U.S. President’s Malaria Initiative (PMI), led by USAID is initiated.

Among all segmentation, Anthelmintic Product Type segment has the highest potential key players are focusing on treating parasitic disease as well as adoption of growing market, in order to strengthen their market presence in the global Antiparasitic Drugs market. For instance, in March 2022, routine inspection FDA officials said in a related announcement that anthelmintic resistance is a problem throughout the world, and resistance can have far-ranging effects where grazing livestock are used to cultivate land and provide transportation in addition to their uses for milk, meat, and fiber.

FDA officials have campaigned for years for practices that preserve the effectiveness of antiparasitic drugs, enlisting veterinarians’ help to change practices on farms. Almost a decade ago, for example, FDA officials delivered presentations to AVMA leaders on the need to encourage use of management practices that preserve anthelmintic effectiveness. 

Global Antiparasitic Drugs Market- Cross Sectional Analysis

Among Applications, Human Health held a dominant position in North America region as well as worldwide over the forecast period due to increasing number of  treatment parasitic disease as well as adoption of growing market, in order to strengthen their market presence in the global Antiparasitic Drugs market. For instance, According to the World Health Organization (WHO), an estimated 6–7 Billion people are infected with T. cruzi worldwide, with about 10,000 deaths every year. In message to commemorate World Chagas Disease Day 2022, WHO’s Director-General, Dr Tedros Adhanom Ghebreyesus, reaffirmed the WHO’s commitment to working alongside  to defeat the disease. “WHO is committed to working side-by-side with all affected countries to increase their ability to prevent, find, report and provide care for every single case, to defeat Chagas disease.”

Global Antiparasitic Drugs Market- Key Developments

AdvaCare’s (global manufacturer of Pharmaceuticals, Antimalarials, Oncology, Supplements, Veterinary Products, and Medical Devices) wide range of anti-malarial treatments is recommended by the World Health Organization (WHO) and commonly administered in regions with malaria outbreaks such as Africa, South America, and Asia.

Available as tablets, injections, and oral suspensions, produce more than 20 effective medications used to prevent and treat multiple types of malaria.

In 2023, Naveen Kumar Reddy Chinnappanna et al., published by Sciendo. The protein kinases, choline transport inhibitors, dihydroorotate dehydrogenase inhibitors, isoprenoid biosynthesis inhibitors, and enzymes involved in the metabolism of lipids and replication of deoxyribonucleic acid, are among the most fascinating antimalarial target proteins presently being investigated. Recent approaches in the drug research and development of novel antimalarial drugs with new targets.

In January 2023, CDC (Centers for Disease Control and Prevention) said that, Travelers choosing drug to prevent Malaria. Recommendations for drugs to prevent malaria differ by country of travel and can be found in Malaria Information by Country. Recommended drugs for each country are listed in alphabetical order and have comparable efficacy in that country.

Global Antiparasitic Drugs Market- Key Trends

Drug Development Strategies for Malaria: With the Hope for New Antimalarial Drug Discovery

Drug Development Strategies for Malaria responsible for the market growth over the forecast period. For instance, in March 2023, a marked reduction in malaria incidence and mortality has been reported in recent years due to the introduction of act in antimalarial policy, the development of drug resistance against most of the antimalarial, especially artemisinin derivatives, is an alarming situation. The introduction of new drugs/combinations in the antimalarial arsenal is an immediate need. Based on resources, one or more of the strategies discussed above should be explored for the development of new chemotherapeutic interventions for malaria. Importantly, the use of genomics and omics-based methodologies has resulted in significant breakthroughs in the identification of novel targets in protozoan diseases.

Global Antiparasitic Drugs Market: Restraints

Rising resistance to antimalarial drug regimens

On a global scale, parasite resistance to artemisinin has been identified in the Greater Mekong subregion and several areas in Africa– notably Eritrea, Rwanda and Uganda. While artemisinin resistance alone rarely leads to treatment failure, resistance to both artemisinin and the partner drug within act drug regimens can lead to high rates of treatment failure, as seen in recent years in parts of the Greater Mekong subregion.

Global Antiparasitic Drugs Market- Key Players

Major players operating in the global Antiparasitic Drugs market include Merck KGaA, GlaxoSmithKline plc, Dr. Reddy’s Laboratories Ltd, Cipla Limited, Cadila Pharmaceuticals, Watson International Limited, Vivaldis, Glenmark Pharmaceuticals Limited, Viatris Inc., Novartis AG, AdvaCare Pharma, Lupin, Sun Pharmaceutical Industries Ltd., and Aurobindo Pharma.

Definition: Antiparasitic drugs are a group of medications used in the management and treatment of infections by parasites, including protozoa, helminthes and ectoparasites. Antiparasitic drugs include several classes of drugs that cover a broad range of diseases caused by parasites.

Share

About Author

Ghanshyam Shrivastava - With over 20 years of experience in the management consulting and research, Ghanshyam Shrivastava serves as a Principal Consultant, bringing extensive expertise in biologics and biosimilars. His primary expertise lies in areas such as market entry and expansion strategy, competitive intelligence, and strategic transformation across diversified portfolio of various drugs used for different therapeutic category and APIs. He excels at identifying key challenges faced by clients and providing robust solutions to enhance their strategic decision-making capabilities. His comprehensive understanding of the market ensures valuable contributions to research reports and business decisions.

Ghanshyam is a sought-after speaker at industry conferences and contributes to various publications on pharma industry.

Missing comfort of reading report in your local language? Find your preferred language :

Frequently Asked Questions

The global Antiparasitic Drugs Market size was valued at USD 23.40 billion in 2023 and is expected to reach USD 34.34 billion in 2030.

Global antiparasitic drugs market is estimated to be valued at US$ 23.40 billion in 2023 and is expected to exhibit a CAGR of 5.6% between 2023 and 2030.

OIE (Office International des Epizooties) guide promotes responsible anthelmintic drug use which drives the market.

Anthelmintic is the leading product type segment in the global antiparasitic drugs market.

Rising resistance to antimalarial drug regimens is expected to hamper the market growth.

Major players operating in the market include Merck KGaA, GlaxoSmithKline plc, Dr. Reddy’s Laboratories Ltd, Cipla Limited, Cadila Pharmaceuticals, Watson International Limited, Vivaldis, Glenmark Pharmaceuticals Limited, Viatris Inc., Novartis AG, AdvaCare Pharma, Lupin, Sun Pharmaceutical Industries Ltd., and Aurobindo Pharma.
Logo

Credibility and Certifications

DUNS Registered

860519526

ESOMAR
Credibility and Certification

9001:2015

Credibility and Certification

27001:2022

Clutch
Credibility and Certification
Logo

Credibility and Certifications

DUNS Registered

860519526

ESOMAR
Credibility and Certification

9001:2015

Credibility and Certification

27001:2022

Clutch
Credibility and Certification

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now

Select a License Type





Logo

Credibility and Certifications

DUNS Registered

860519526

ESOMAR
Credibility and Certification

9001:2015

Credibility and Certification

27001:2022

Clutch
Credibility and Certification

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.